Effects of Multifocal Contact Lens on Ocular Tissue

June 18, 2018 updated by: Johnson & Johnson Vision Care, Inc.

Effects on Ocular Tissues of Vistakon® Investigational Multifocal Contact Lenses - Asian Population Study

The purpose of this study is to evaluate the etafilcon - PVP (multi-focal)

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. The subject must read, understand, and sign the statement of Informed Consent and receive a fully executed copy of the form.
  2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  3. The subject must be between 40 and 70 years of age.
  4. The subject's vertex corrected spherical equivalent distance refraction must be in the range of 1.00 too -5.75 in each eye.
  5. The subject must identify themselves as Asian by self-report and have eyes and eyelids with an automatically Asian appearance.
  6. The subject's refractive cylinder must be less than or equal to -0.75D in each eye.
  7. The subject's ADD power must be in the range of +0.75 D to +2.5 D in each eye.
  8. The subject must have best corrected visual acuity of 20/20-3 or better in each eye.
  9. Subjects own a wearable pair of spectacles, if required for their distance vision.
  10. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 5 days per week for at least 8 hours per day, for one month or more duration).
  11. The subject must already be wearing a presbyopic contact lens correction (e.g. reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".

Exclusion Criteria:

  1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued)
  2. Any ocular or systemic allergies that contraindicate contact lens wear.
  3. Any ocular or systemic disease, autoimmune disease, or use of medication, that will contraindicate contact lens wear.
  4. Any ocular abnormality that may interfere with contact lens wear.
  5. Use of any ocular medications, with the exception of rewetting drops.
  6. Any previous intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.).
  7. Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) which may contraindicate contact lens wear.
  8. History of herpetic keratitis.
  9. Any ocular infection or inflammation.
  10. Any corneal distortion or irregular cornea.
  11. History of binocular vision abnormality or strabismus.
  12. Any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV).
  13. History of diabetes.
  14. Habitual wearer of etafilcon-A contact lens material.
  15. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: etafilcon - PVP (multi-focal)
The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
The investigational contact lens must be worn at least six hours daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Upper Eye Lid Margin Staining
Time Frame: 30 days Post wear
Upper Eye Lid Margin Staining is assessed via Ocular Photography using proprietary algorithm. The average grade across upper eye lid margin was reported in mm^2.
30 days Post wear
Limbal Staining
Time Frame: 30 Days Post Wear
Measured via Ocular Photography using proprietary algorithm. The limbal conjunctival lissamine green staining average surface area in % of the overall limbal area was reported.
30 Days Post Wear
Corneal Staining
Time Frame: 30 Days Post Wear
The corneal fluorescein staining average surface area in % of the upper corneal quadrant was reported.
30 Days Post Wear

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2014

Primary Completion (Actual)

May 1, 2015

Study Completion (Actual)

May 1, 2015

Study Registration Dates

First Submitted

January 19, 2015

First Submitted That Met QC Criteria

January 23, 2015

First Posted (Estimate)

January 26, 2015

Study Record Updates

Last Update Posted (Actual)

June 19, 2018

Last Update Submitted That Met QC Criteria

June 18, 2018

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • CR-5632

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Visual Acuity

Clinical Trials on etafilcon - PVP (multi-focal)

Subscribe